Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES1 | P23141 | 6/20 | 0.55 |
| ▸ | TGM2 | P21980 | 6/20 | 0.53 |
| ▸ | MAOA | P21397 | 6/20 | 0.50 |
| ▸ | MAOB | P27338 | 6/20 | 0.50 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.50 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.43 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.42 |
| ▸ | CASP3 | P42574 | 1/20 | 0.40 |
| ▸ | BCHE | P06276 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2498450 | 0.85 | TGM2 (0.55) | CES1TGM2MAOAMAOBPDPK1 | |
| SCHEMBL30639075 | 0.85 | TGM2 (0.55) | CES1TGM2MAOAMAOBPDPK1 | |
| SCHEMBL21708144 | 0.85 | CHEK1 (0.43) | CES1TGM2MAOAMAOBCHEK1 | |
| Hydrochloric Acid SCHEMBL11430847 | 0.84 | TGM2 (0.53) | CES1TGM2MAOAMAOBPDPK1 | |
| SCHEMBL24311515 | 0.82 | CHEK1 (0.48) | CES1TGM2CHEK1PDPK1LRRK2 | |
| SCHEMBL4855393 | 0.75 | CHEK1 (0.60) | CES1TGM2CHEK1PDPK1 | |
| SCHEMBL2809485 | 0.75 | GRM5 (0.59) | MAOAMAOBCHEK1PDPK1CASP3 | |
| SCHEMBL2258909 | 0.73 | GSK3B (0.42) | MAOAMAOBCHEK1 | |
| SCHEMBL30398896 | 0.72 | CES1 (0.62) | CES1TGM2MAOAMAOBLRRK2 | |
| SCHEMBL4192180 | 0.72 | CES1 (0.62) | CES1TGM2MAOAMAOBLRRK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11545633-B2 | 3,7-bis(2-oxoindolin-3-ylidene)benzo[1,2-b:4,5-b′]difuran-2,6-dione dicyanide-based materials and uses thereof in organic electronic devices | NATIONAL RESEARCH COUNCIL OF CANADA (CA) | 2023-01-03 | — | — | US | disclosed |
| EP-3765457-A1 | 3,7-BIS(2-OXOINDOLIN-3-YLIDENE)BENZO[1,2-B:4,5-B']DIFURAN-2,6-DIONE DICYANIDE-BASED MATERIALS AND USES THEREOF IN ORGANIC ELECTRONIC DEVICES | National Research Council of Canada (CA) | 2021-01-20 | — | — | EP | disclosed |
| US-20210013424-A1 | 3,7-BIS(2-OXOINDOLIN-3-YLIDENE)BENZO[1,2-B:4,5-B']DIFURAN-2,6-DIONE DICYANIDE-BASED MATERIALS AND USES THEREOF IN ORGANIC ELECTRONIC DEVICES | NATIONAL RESEARCH COUNCIL OF CANADA (CA) | 2021-01-14 | — | — | US | disclosed |
| WO-2019175804-A1 | 3,7-BIS(2-OXOINDOLIN-3-YLIDENE)BENZO[1,2-B:4,5-B']DIFURAN-2,6-DIONE DICYANIDE-BASED MATERIALS AND USES THEREOF IN ORGANIC ELECTRONIC DEVICES | NATIONAL RESEARCH COUNCIL OF CANADA (CA) | 2019-09-19 | — | — | WO | disclosed |
| US-9688678-B2 | Oxindole compounds carrying a nitrogen-bound spiro substituent and use thereof for treating vasopressin-related diseases | AbbVie Deutschland GmbH & Co. KG (DE) | 2017-06-27 | — | — | US | disclosed |
| EP-3143024-A1 | OXINDOLE COMPOUNDS CARRYING A NITROGEN-BOUND SPIRO SUBSTITUENT AND USE THEREOF FOR TREATING VASOPRESSIN-RELATED DISEASES | AbbVie Deutschland GmbH & Co. KG (DE) | 2017-03-22 | — | — | EP | disclosed |
| US-20150329551-A1 | OXINDOLE COMPOUNDS CARRYING A NITROGEN-BOUND SPIRO SUBSTITUENT AND USE THEREOF FOR TREATING VASOPRESSIN-RELATED DISEASES | AbbVie Deutschland GmbH & Co. KG (DE) | 2015-11-19 | — | — | US | disclosed |
| WO-2015173393-A1 | OXINDOLE COMPOUNDS CARRYING A NITROGEN-BOUND SPIRO SUBSTITUENT AND USE THEREOF FOR TREATING VASOPRESSIN-RELATED DISEASES | AbbVie Deutschland GmbH & Co. KG (DE) | 2015-11-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210013424-A1 | 3,7-BIS(2-OXOINDOLIN-3-YLIDENE)BENZO[1,2-B:4,5-B']DIFURAN-2,6-DIONE DICYANIDE-BASED MATERIALS AND USES THEREOF IN ORGANIC ELECTRONIC DEVICES | TDO2, SCO2, DBF4 | CES1 4806/4885TGM2 4212/4885MAOA 2530/4885 |
| US-20150329551-A1 | OXINDOLE COMPOUNDS CARRYING A NITROGEN-BOUND SPIRO SUBSTITUENT AND USE THEREOF FOR TREATING VASOPRESSIN-RELATED DISEASES | AVPR2, AVPR1B, AVPR1A | CES1 2207/4885TGM2 4384/4885MAOA 1159/4885 |
| US-11545633-B2 | 3,7-bis(2-oxoindolin-3-ylidene)benzo[1,2-b:4,5-b′]difuran-2,6-dione dicyanide-based materials and uses thereof in organic electronic devices | SCO2, TDO2, DBF4 | CES1 4807/4885TGM2 4215/4885MAOA 2568/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.